BioNTech, Medigene Ink Immunotherapy Pact Against Cancer
BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaborat...